The SME IPO of Asston Pharmaceuticals drew robust demand from investors on Day 3, with the issue subscribed over 32 times ahead of its July 11 close. Retail investors led the charge with over 37x subscription, followed by HNIs at more than 51x, while QIBs bid nearly 8x their quota.
Comments
Post a Comment